Forbius’ AVID200, a Novel TGF-beta 1 & 3 Inhibitor, Cleared by Health Canada to Commence Phase 1 Clinical Trial in Solid Tumors

Jennifer Schram Forbius (Formation Biologics), Portfolio News, Press Release